Login to Your Account

LONDON – The extent to which big pharma has piled into rare disease research is highlighted in a new study of patents in the field launched at the Biotechnology Industry Organization meeting on Monday.

Summer has been slow to arrive in Europe this year, a blessing for patients with erythropoietic protoporphyria, an extreme sensitivity to sunlight, who have been awaiting the market rollout of the first approved treatment, Scenesse.

LONDON – Restructuring and reshaping of the pharma industry across the globe has resulted in significant fallout in terms of programs, redundant facilities and skills. At the same time there has been significant externalization of R&D.
More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: